Technical Analysis for CNTB - Connect Biopharma Holdings Limited
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 20 DMA | Bearish | -2.96% | |
| 50 DMA Support | Bullish | -2.96% | |
| MACD Bullish Signal Line Cross | Bullish | -2.96% | |
| Narrow Range Bar | Range Contraction | -2.96% | |
| Inside Day | Range Contraction | -2.96% | |
| Wide Bands | Range Expansion | -2.96% | |
| 20 DMA Support | Bullish | -6.05% | |
| 50 DMA Support | Bullish | -6.05% | |
| Outside Day | Range Expansion | -6.05% | |
| Wide Bands | Range Expansion | -6.05% |
| Alert | Time |
|---|---|
| 10 DMA Support | about 1 hour ago |
| Down 3% | about 1 hour ago |
| Fell Below 50 DMA | about 1 hour ago |
| Fell Below Previous Day's Low | about 1 hour ago |
| Down 2 % | about 1 hour ago |
Get this analysis on your stocks daily!
- Earnings date: 04/15/2024
Connect Biopharma Holdings Limited Description
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmune-related inflammation diseases; CBP-174, a small molecule histamine receptor 3 antagonist for oral administration, which is in a preclinical stage to treat chronic itch associated with skin inflammation; and CBP-233, a preclinical stage humanized antibody against interleukin-33, a cytokine involved in T helper 2 inflammation. The company was founded in 2012 and is headquartered in Taicang, China.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Biology Immunology Immune System Immunotherapy Inflammation Asthma Atopic Dermatitis Chronic Rhinosinusitis Human Physiology Skin Inflammation Animal Physiology Interleukins Nasal Polyps
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 2.84 |
| 52 Week Low | 0.5347 |
| Average Volume | 128,689 |
| 200-Day Moving Average | 1.18 |
| 50-Day Moving Average | 1.48 |
| 20-Day Moving Average | 1.54 |
| 10-Day Moving Average | 1.45 |
| Average True Range | 0.18 |
| RSI (14) | 50.00 |
| ADX | 20.39 |
| +DI | 17.54 |
| -DI | 13.63 |
| Chandelier Exit (Long, 3 ATRs) | 1.74 |
| Chandelier Exit (Short, 3 ATRs) | 1.83 |
| Upper Bollinger Bands | 1.87 |
| Lower Bollinger Band | 1.20 |
| Percent B (%b) | 0.47 |
| BandWidth | 43.54 |
| MACD Line | -0.02 |
| MACD Signal Line | -0.02 |
| MACD Histogram | 0.0019 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.66 | ||||
| Resistance 3 (R3) | 1.66 | 1.61 | 1.63 | ||
| Resistance 2 (R2) | 1.61 | 1.58 | 1.61 | 1.62 | |
| Resistance 1 (R1) | 1.57 | 1.56 | 1.55 | 1.57 | 1.62 |
| Pivot Point | 1.52 | 1.52 | 1.51 | 1.52 | 1.52 |
| Support 1 (S1) | 1.48 | 1.49 | 1.46 | 1.48 | 1.42 |
| Support 2 (S2) | 1.43 | 1.47 | 1.43 | 1.42 | |
| Support 3 (S3) | 1.39 | 1.43 | 1.41 | ||
| Support 4 (S4) | 1.39 |
